Prognose
Analytikernes gennemsnitlige kursmål er 8,20 € (+187,72 %). Medianen er 8,20 € (+187,72 %).
| Køb |
4 |
| Behold |
0 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Entera Bio gets shortened FDA approval pathway for oral osteoporosis drug EB613
The FDA has agreed to a shortened approval study design for EB613: a 12-month, double-blind, placebo-controlled Phase III trial instead of the originally planned 24 months. Entera Bio raised $275 million and plans to begin recruitment in 2026. EB613 is an oral teriparatide tablet targeting patients who refuse injectable therapies; in Phase II it showed total-hip BMD increases of 1.34–1.57% after six months. Despite the milestone, the stock fell sharply on the conference day as investors remain cautious pending additional efficacy and safety data. » Mere på de.investing.com
Entera Bio posts wider Q2 loss as it ramps R&D ahead of EB613 Phase 3
Entera Bio reported a Q2 net loss of $7.3 million, or $0.14 per share, versus analyst expectations of a $0.09 per-share loss, driven by a $2.7 million non-cash warrant remeasurement and higher R&D spending. R&D rose to $3.2 million as the company prepares registrational work for its oral osteoporosis candidate EB613 after reaching FDA alignment on a 12-month Phase 3 design. Entera plans to start the pivotal trial in late 2026 with topline results targeted in H2 2028 and completed a $275 million private placement expected to extend its cash runway into 2030 (cash was $11.3 million at June 30). » Mere på finance.yahoo.com
Entera Bio secures $10 million in private placement led by BVF Partners
Entera Bio completed a private placement of approximately $10 million, issuing 7,827,789 units at $1.2775 each; each unit includes a common share or a pre-funded warrant and a five-year warrant to purchase 1.5 shares at $1.24. Gross proceeds are about $10 million; if the warrants are fully exercised, an additional roughly $14.5 million could be raised, bringing total potential proceeds to about $24.5 million. Entera intends to use the funds to start the pivotal Phase 3 trial of EB613 in postmenopausal women with osteoporosis and for working capital; the company notes a strong liquidity position (current ratio 6.94). The stock rose 26% last week and is currently trading at $1.22, though InvestingPro considers the shares overvalued at this level. » Mere på de.investing.com
Entera Bio secures $10 million private placement led by BVF Partners
Entera Bio completed a private placement of approximately 7,827,789 units at $1.2775 each, led by funds affiliated with BVF Partners, expected to generate gross proceeds of about $10 million. Each unit consists of a common share or a prepaid warrant plus a five-year warrant to purchase 1.5 common shares at $1.24; if fully exercised, additional proceeds of roughly $14.5 million could be raised (potential total proceeds ~ $24.5 million). The proceeds are intended to fund the phase 3 study of EB613 for the treatment of postmenopausal osteoporosis and for general corporate purposes; the securities are being offered pursuant to Section 4(a)(2). » Mere på de.investing.com
Entera Bio to file phase‑3 protocol for EB613 in Q1 2026
Entera Bio will submit the final phase‑3 protocol for EB613, an oral PTH tablet for osteoporosis, to the FDA in Q1 2026. The filing follows the FDA’s December 2025 recognition of bone mineral density (BMD) as an approval‑relevant endpoint. The company expects results from an ongoing phase‑1 bridging study of the next‑gen formulation by the end of Q1 2026 and plans to accelerate development of EB612 for hypoparathyroidism in 2026. According to analysis, Entera shows a high current ratio of 10.83 and is in talks about strategic partnerships, but remains a loss‑making and volatile biotech stock. » Mere på de.investing.com
Virksomhedstal
I det seneste kvartal havde ENTERA BIO IS-,0000769 en omsætning på 0 € og et nettoresultat på -13,77 mio. €
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 0 | - |
| Bruttofortjeneste | 0 | 100,00 % |
| Nettoresultat | -13,77 mio. | 404,98 % |
| EBITDA | -6,41 mio. | 135,51 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 517,36 mio. € |
Antal aktier | 174,14 mio. |
Højeste/laveste i 52 uger | 3,83 € - 0,83 € |
| Udbytte | Nej |
Beta | 1,46 |
P/E (PE Ratio) | -8,39 |
PEG (PEG Ratio) | 0,19 |
K/I (PB Ratio) | 1,72 |
P/S (PS Ratio) | 0,00 |
Virksomhedsprofil
Entera Bio Ltd. er et klinisk fase-biofarmaceutisk selskab, der fokuserer på udvikling og kommercialisering af oralt administrerede store molekylære terapeutika til uopfyldte medicinske behov. Selskabets vigtigste lægemiddelkandidater omfatter EB612, som er i fase II-kliniske forsøg til behandling af hypoparathyreoidisme; og EB613, som har gennemført fase II-kliniske forsøg til behandling af osteoporose, samt er i fase I-kliniske forsøg til behandling af non-union-frakturer. Selskabet har en forsknings- og licensaftale med Amgen Inc. om udvikling og opdagelse af kliniske kandidater inden for inflammatoriske sygdomme og andre alvorlige sygdomme. Entera Bio Ltd. blev stiftet i 2009 og har hjemsted i Jerusalem, Israel.
| Navn | ENTERA BIO IS-,0000769 |
| CEO | Miranda J. Toledano |
| Hjemsted | Jerusalem,
jm Israel |
| Websted | |
| Sektor | Dagligvarer |
| Branche | Fødevarer |
| Børsnotering | 28.06.2018 |
| Medarbejdere | 27 |
Deep Dive
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | ENTX |
Frankfurt | 5DT.F |
Düsseldorf | 5DT.DU |